These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38814342)

  • 1. Oral docetaxel plus encequidar - a phase 1 clinical trial.
    Wang D; Hung N; Hung T; Eden K; Chan WK; Kwan R; Qin A; Chang C; Duffull S; Glue P; Jackson C
    Cancer Chemother Pharmacol; 2024 Sep; 94(3):475-481. PubMed ID: 38814342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral docetaxel plus encequidar - A pharmacokinetic model and evaluation against IV docetaxel.
    Wang D; Jackson C; Hung N; Hung T; Kwan R; Chan WK; Qin A; Hughes-Medlicott NJ; Glue P; Duffull S
    J Pharmacokinet Pharmacodyn; 2024 Aug; 51(4):335-352. PubMed ID: 38504032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic study.
    Jackson CGCA; Hung T; Segelov E; Barlow P; Prenen H; McLaren B; Hung NA; Clarke K; Chao TY; Dai MS; Yeh HT; Cutler DL; Kramer D; He J; Zhi J; Chan WK; Kwan R; Deva S
    Br J Clin Pharmacol; 2021 Dec; 87(12):4670-4680. PubMed ID: 33960504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma.
    Kreis W; Budman DR; Fetten J; Gonzales AL; Barile B; Vinciguerra V
    Ann Oncol; 1999 Jan; 10(1):33-8. PubMed ID: 10076719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093).
    Kuppens IE; Bosch TM; van Maanen MJ; Rosing H; Fitzpatrick A; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2005 Jan; 55(1):72-8. PubMed ID: 15316750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of vinorelbine and low-dose docetaxel in chemotherapy-naive patients with hormone-refractory prostate cancer.
    Koletsky AJ; Guerra ML; Kronish L
    Cancer J; 2003; 9(4):286-92. PubMed ID: 12967139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study.
    Dai MS; Chao TC; Chiu CF; Lu YS; Shiah HS; Jackson CGCA; Hung N; Zhi J; Cutler DL; Kwan R; Kramer D; Chan WK; Qin A; Tseng KC; Hung CT; Chao TY
    Ther Adv Med Oncol; 2023; 15():17588359231183680. PubMed ID: 37492633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Sensitive Assay for Unbound Docetaxel Using Ultrafiltration plus HPLC-MS and Its Application to a Clinical Study.
    Wang D; Hughes-Medlicott N; Klingler L; Wang Y; Hung N; Duffull S; Hung T; Glue P; Qin A; Kwan R; Chan WK; Jackson C
    Pharmaceutics; 2024 Apr; 16(5):. PubMed ID: 38794263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of docetaxel and ritonavir after oral administration of ModraDoc006/r in patients with prostate cancer versus patients with other advanced solid tumours.
    Vermunt MAC; van der Heijden LT; Hendrikx JJMA; Schinkel AH; de Weger VA; van der Putten E; van Triest B; Bergman AM; Beijnen JH
    Cancer Chemother Pharmacol; 2021 Jun; 87(6):855-869. PubMed ID: 33744986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.
    Savona MR; Odenike O; Amrein PC; Steensma DP; DeZern AE; Michaelis LC; Faderl S; Harb W; Kantarjian H; Lowder J; Oganesian A; Azab M; Garcia-Manero G
    Lancet Haematol; 2019 Apr; 6(4):e194-e203. PubMed ID: 30926081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients: A phase Ib study.
    Vermunt MAC; Robbrecht DGJ; Devriese LA; Janssen JM; Thijssen B; Keessen M; van Eijk M; Kessels R; Eskens FALM; Beijnen JH; Mehra N; Bergman AM
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1367. PubMed ID: 33709626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer.
    Abramson VG; Oliveira M; Cervantes A; Wildiers H; Patel MR; Bauer TM; Bedard PL; Becerra C; Richey S; Wei MC; Reyner E; Bond J; Cui N; Wilson TR; Moore HM; Saura C; Krop IE
    Breast Cancer Res Treat; 2019 Nov; 178(1):121-133. PubMed ID: 31368034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients.
    Bousquet G; Alexandre J; Le Tourneau C; Goldwasser F; Faivre S; de Mont-Serrat H; Kaiser R; Misset JL; Raymond E
    Br J Cancer; 2011 Nov; 105(11):1640-5. PubMed ID: 22027711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
    Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer.
    Bhargava P; Marshall JL; Fried K; Williams M; Lefebvre P; Dahut W; Hanfelt J; Gehan E; Figuera M; Hawkins MJ; Rizvi NA
    Cancer Chemother Pharmacol; 2001 Aug; 48(2):95-103. PubMed ID: 11561784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
    Dreicer R; Petrylak D; Agus D; Webb I; Roth B
    Clin Cancer Res; 2007 Feb; 13(4):1208-15. PubMed ID: 17317831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer.
    Smit EF; Garon EB; Reck M; Cappuzzo F; Bidoli P; Cohen RB; Gao L; O'Brien LM; Lee P; Zimmermann A; Ferry DR; Melemed AS; Pérol M
    Cancer Chemother Pharmacol; 2018 Jul; 82(1):77-86. PubMed ID: 29721850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Population Pharmacokinetic Model of Oral Docetaxel Coadministered With Ritonavir to Support Early Clinical Development.
    Yu H; Janssen JM; Sawicki E; van Hasselt JGC; de Weger VA; Nuijen B; Schellens JHM; Beijnen JH; Huitema ADR
    J Clin Pharmacol; 2020 Mar; 60(3):340-350. PubMed ID: 31595980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies.
    Ma WW; Li JJ; Azad NS; Lam ET; Diamond JR; Dy GK; Opyrchal M; Zhi J; Kramer D; Chan WK; Cutler D; Kwan R; Adjei AA; Jimeno A
    Cancer Chemother Pharmacol; 2022 Jul; 90(1):7-17. PubMed ID: 35731258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors.
    Amin M; Gao F; Terrero G; Picus J; Wang-Gillam A; Suresh R; Ma C; Tan B; Baggstrom M; Naughton MJ; Trull L; Belanger S; Fracasso PM; Lockhart AC
    Am J Clin Oncol; 2021 Sep; 44(9):443-448. PubMed ID: 34310349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.